The Immunohistochemistry Antibody Company
LIFESPAN BIOSCIENCES EXPANDS IHC-PLUSTM ANTIBODIES PRODUCT LINE
Worldwide Demand for Immunohistochemistry (IHC) Validated Antibodies Fuels Company's Rapid Growth in $2 Billion Reagent Antibody Market
SEATTLE—April 19, 2010 — LifeSpan BioSciences, Inc., a leading provider of antibodies for thousands of researchers worldwide, has increased the number of validated IHC-plusTM antibodies available in its catalog to more than 3,500. With this increase, LifeSpan is well on its way to building the world's largest catalog of well characterized, IHC-validated reagent antibodies. Overall, LifeSpan has a catalog of more than 82,000 antibodies.
IHC-plusTM antibodies, LifeSpan's flagship product line, consists of antibodies that LifeSpan has validated for use in IHC drawing on its 15-year track record in designing, making and using antibodies for immunohistochemistry. These antibodies have been extensively tested against formalin-fixed paraffin-embedded (FFPE) human tissues. Each antibody has been characterized at four different concentrations against 22 normal human tissues, plus additional controls. These antibodies have been identified as the best reagents for use in FFPE-IHC.
Immunohistochemistry is widely used to visualize proteins in tissues, and can detect any protein encoded by the 21,000 genes in the human genome. In addition, IHC can detect functionally important protein modifications. To visualize an antibody-antigen interaction with IHC, tissue specimens are fixed in formalin and embedded in wax, and thin sections are placed on microscope slides. After incubation with an antibody, the bound antibody is stained with a dye, and the slides are examined under a microscope by a pathologist to detect specific molecular markers.
"Our 15-year history in delivering IHC services and validating antibodies makes LifeSpan uniquely qualified to meet the need for high-quality, IHC-validated antibodies to thousands of new protein targets," said Glenna Burmer, M.D., Ph.D., chief scientific officer and executive vice president. "LifeSpan is rapidly becoming the market leader for these important antibody reagents."
LifeSpan has grown its antibody business exponentially over the past three years, and thousands of researchers in more than 50 countries across Europe, Asia and North America now rely on LifeSpan BioSciences for their antibodies.
"With our rapidly expanding product line, our reagent antibody revenues have increased rapidly over the past few years and we expect them to continue to do so," said LifeSpan's CEO, Joe Brown, Ph.D. "In 2010, we are continuing to aggressively expand our antibody catalog of IHC-plusTM antibodies to create value for our customers and strategic partners, and to strengthen our business for the future."
About LifeSpan BioSciences, Inc.